Despite positive clinical data, copyright's Vyndamax, a treatment for hereditary transthyretin-mediated amyloidosis (hATTR), is encountering significant resistance from PBMs. Such companies are typically building obstacles to access, such as high cost criteria and PA that limit user opportunity. Industry indicate that these coverage hurdles crea… Read More